Milner Therapeutics Institute

What Milner Therapeutics Institute does

The Milner Therapeutics Institute is a non-profit research institute within the University of Cambridge that connects academic research with pharmaceutical industry to drive therapeutic discovery. It operates from the Jeffrey Cheah Biomedical Centre on the Cambridge Biomedical Campus and delivers its mission through three pillars: Research, Partnerships, and Enterprise. Its research arm comprises the Target Discovery Group, the Functional Genomics Screening Laboratory (FGSL, a collaboration with MRC and AstraZeneca enabling whole-genome-scale arrayed CRISPR screening for chronic diseases), and the AI and Computational Research Group applying AI and quantum computing to large patient and tissue datasets for target identification.

The Partnerships pillar centres on the Milner Therapeutics Consortium — a membership body of ten pharmaceutical companies and three academic institutions — alongside an extended affiliate community of 80+ companies and >90 academic, industry, and investor organisations. Consortium and affiliate members co-fund research and gain privileged access to translational pipelines, while flagship events such as the annual Symposium (~500 in-person and 250+ online attendees), Milner Pitch Day, the Seminar Series, and the Cambridge AI Club for biomedicine serve as convening and deal-flow channels.

The Enterprise pillar is anchored by the Milner Bio-incubator, which houses roughly ten early-stage therapeutics and AI-bio startups across one Biomedical Campus hub and two City Centre hubs. Adjacent initiatives include the Founders Growth Community (pre-Series A workshops and masterclasses) and Affiliated Venture Partners (Cambridge Innovation Capital, Cambridge Enterprise, o2h Ventures, Meltwind Advisory). Recent strategic expansions include partnerships with Flagship Pioneering and Cambridge University Health Partners (2025), the addition of Daiichi Sankyo as the consortium's tenth pharma member (September 2025), the OBN Award for FGSL (November 2025), and bio-incubator alumni raising major rounds including Immutrin's £65M Series A (March 2026) and TRIMTECH Therapeutics' $31M seed (2025).

Name

Milner Therapeutics Institute

Legal name

Milner Therapeutics Institute, University of Cambridge

Website

https://milner.cam.ac.uk

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

The Milner Therapeutics Institute is a University of Cambridge non-profit research institute that bridges academic discovery and pharmaceutical industry through a Therapeutics Consortium of ten pharma partners, a Bio-incubator for early-stage biotech startups, and research programmes in functional genomics, target discovery, and AI-driven computational biology.

Ownership category

akta.pro rank

Product category

Academic Translational Research Institute

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Therapeutics research institute
• Academic industry partnerships
• Biotech incubator services
• Functional genomics screening
• Pharma consortium collaboration

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Academic Research Funding: The institute operates as part of the University of Cambridge, funded through research grants, academic funding bodies, and industry partnerships. Revenue supports research operations, facilities maintenance, and consortium activities.
2. Consortium Membership and Partnership Fees: Pharma partners and affiliates pay membership fees to join the Milner Therapeutics Consortium, gaining access to research collaborations, networking events, and the broader biotech ecosystem.
3. Bio-incubator Lab Space Rental: Start-ups and SMEs rent space and facilities through the Bio-incubator, which provides unique environment for companies to work alongside startups, pharma and academic scientists.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels9 records

Core offering

The Milner Therapeutics Institute is a University of Cambridge research institute that connects academic research with the pharmaceutical industry to drive therapeutic discoveries. It operates three pillars — Research (Target Discovery, AI and Computational Research, Functional Genomics Screening Laboratory), Partnerships (a Therapeutics Consortium of 10 pharma partners and 3 academic institutions plus an 80+ company affiliate network), and Enterprise (a multi-hub Bio-incubator hosting ~10 startups, plus entrepreneurship programmes, the Founders Growth Community, Pitch Day, and the annual Therapeutics Symposium).

Product overview

The Milner Therapeutics Institute connects academic research with industry to drive therapeutic discoveries through three strategic pillars: Research, Partnerships, and Enterprise. The institute operates research groups (AI and Computational Research, Target Discovery, Functional Genomics Screening Laboratory) that develop human disease models and apply AI and computational approaches to identify drug targets. The Enterprise pillar includes a bio-incubator providing lab facilities and support for early-stage biotech companies, alongside an annual Therapeutics Symposium, Cambridge AI Club for computational biology discussions, Milner Seminar Series, and Pitch Day events. The Partnerships pillar comprises a Therapeutics Consortium of 10 pharma partners and 3 academic institutions, plus an extended network of 80+ affiliated companies, all driving collaborative therapeutics strategies. The institute bridges university research with commercial pharmaceutical development through these interconnected programs.

Differentiator

Problem solved

Functional benefit

Brands

• Milner Bio-incubator: A bio-incubator providing space and facilities for start-ups and SMEs focused on therapeutic research, with three hubs including Biomedical Campus hub and City Centre hubs.
• Cambridge AI Club
• Milner Therapeutics Symposium
• Milner Pitch Day
• Founders Growth Community

Products and services

• Milner Bio-incubator Three-hub incubation facility (Biomedical Campus hub and two City Centre hubs) providing state-of-the-art lab equipment, meeting rooms, and kitchenette facilities for R&D-intensive biotech startups for up to 24 months. Currently houses around 10 startups including Avatrial, Bind Research, Cambridge GenetiX, Clock.Health, CoSyne Therapeutics, Elastin Biosciences, GeneNet Technology, Healthspan Biotics, Immutrin, New Platelet Company, and Shift Bioscience.
• Therapeutics Consortium A membership-based community of 10 pharma partners (including AstraZeneca, GSK, and Daiichi Sankyo) and 3 academic institutions that drive therapeutic discovery through cross-sector partnerships and collaborative research initiatives.
• Functional Genomics Screening Laboratory (FGSL) State-of-the-art facility for arrayed CRISPR screening using robotics, enabling screens ranging from tens to hundreds of genes through to whole-genome scale for chronic disease research. A collaboration between Milner Therapeutics Institute, MRC, and AstraZeneca.
• Milner Therapeutics Symposium Annual flagship event hosting approximately 500 in-person and 250+ online delegates from academia and industry, featuring plenary talks, spotlight presentations from bio-incubator startups, and panels on therapeutic discovery. Free to academics and open to Milner-affiliated companies.
• Milner Pitch Day Annual showcase where emerging biotech companies from the bio-incubator and selected national/international companies pitch to investors and corporate ventures.
• Cambridge AI Club for Biomedicine Monthly forum for the Biomedical AI and Machine Learning community in Cambridge featuring talks, panel discussions, and networking over refreshments at the Jeffrey Cheah Biomedical Centre.
• Founders Growth Community Collaborative initiative providing workshops, masterclasses, roundtables, and panel discussions for pre-Series A life science and biotech founders to accelerate funding and growth within an ecosystem of 80+ affiliated global pharma and biotech companies.
• Milner Seminar Series Interdisciplinary seminar series featuring speakers from academia and industry addressing common themes in disease and therapeutic approaches, followed by networking opportunities over refreshments.

Quantifiable outcome

• Immutrin raised £65 million ($87 million) Series A funding while in the Bio-incubator.
• +2 more outcomes

Named customers12 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature3 records

Partnerships

13 partnerships are on record, tiered core and flagship.

• Cambridge EnterprisecoreStrategic or Co-development Partner · 1 April 2026Jointly welcomed Curie.Bio to Cambridge, co-organising events and providing translational support for University researchers.
• Daiichi SankyocoreStrategic or Co-development Partner · 1 September 2025Daiichi Sankyo joined the Milner Therapeutics Consortium as the tenth pharma partner, working with the Milner team to advance research towards new therapeutics across multiple disease areas.
• Flagship PioneeringflagshipStrategic or Co-development Partner · 1 January 2025Collaboration between Milner Therapeutics Institute, Cambridge University Health Partners, and Flagship Pioneering brings together Flagship's ecosystem of 40+ life sciences companies with Cambridge researchers and clinicians to accelerate biotech research and innovation. Quotient Therapeutics is an early outcome of this partnership.
• Medical Research Council (MRC)coreStrategic or Co-development PartnerMRC collaborates with Milner Therapeutics Institute and AstraZeneca on the Functional Genomics Screening Laboratory (FGSL), providing funding and expertise for arrayed CRISPR screening research for chronic diseases.
• AstraZenecacoreStrategic or Co-development PartnerAstraZeneca is a key pharma partner in the FGSL collaboration with MRC and Milner Therapeutics Institute, contributing to the development of biomarkers and therapeutics for chronic diseases through functional genomics.
• Start CodoncoreStrategic or Co-development PartnerCambridge-based biotech accelerator that identifies and supports transformative life science companies. Start Codon was established with CIC facilitation and absorbed into CIC after raising over £50 million.
• Babraham Research CampuscoreStrategic or Co-development PartnerPartner in the Founders Growth Community, providing workshops, masterclasses, and networking for pre-Series A life science/BioTech founders alongside Milner Therapeutics Institute.
• o2h groupcoreStrategic or Co-development PartnerCo-founder of Founders Growth Community, contributing to the ecosystem of workshops and networking for life science founders in the Cambridge region.
• Wellcome Genome CampuscoreStrategic or Co-development PartnerPartner in the Founders Growth Community, supporting education and community development for biotech founders.
• Cancer Research UK - Florian Markowetz's GroupcoreStrategic or Co-development PartnerJoint organiser of the Cambridge AI Club for Biomedicine, bringing together the Biomedical AI and Machine Learning community for computational biology discussions.
• Cambridge EnterprisecoreStrategic or Co-development PartnerAffiliate Venture Partner supporting technology transfer and startup development in the Cambridge ecosystem.
• University of CambridgecoreOthersThe institute is part of the University of Cambridge, operating from the Jeffrey Cheah Biomedical Centre on the Cambridge Biomedical Campus.
• Cambridge University Health PartnerscoreStrategic or Co-development PartnerHealth partners collaborating with Milner on Flagship Pioneering partnership and broader translational initiatives.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Babraham Research Campus: Cambridge-based life sciences research campus with bio-incubator facilities and startup support programs; Milner recently co-located with Babraham partners (TRIMTECH, Epitopea) and Babraham is an active partner in Milner's Founders Growth Community, making it the most directly comparable peer for incubation and translational research.
• Francis Crick Institute: London-based biomedical research institute that bridges discovery science and clinical translation through industry partnerships and startup support; comparable to Milner as a UK translational research institute coupling academic research with industry collaboration and spinout activity.
• Broad Institute: MIT/Harvard-affiliated research organization that integrates genomics, functional genomics (including CRISPR screening), and AI-driven biology with industry partnerships and a startup ecosystem; directly comparable as an academic-industry translational model in life sciences, including its own bio-incubator activities.
• MRC Laboratory of Molecular Biology: Cambridge-based MRC research institute operating at the leading edge of molecular biology with a strong track record of spinouts into therapeutic companies; comparable as a Cambridge neighbour in fundamental life science research feeding therapeutic translation.
• Cambridge Innovation Capital: Cambridge-focused venture capital firm that has invested in multiple Milner-related biotech companies and absorbed Start Codon accelerator; closely comparable as a Cambridge ecosystem investor and accelerator operator central to the same biotech startup pipeline Milner supports.
• Start Codon: Cambridge biotech accelerator that identified and supported transformative life science companies before being absorbed into CIC; directly comparable as a former peer accelerator in the same Milner Pitch Day ecosystem that supported similar early-stage therapeutic startups.
• Flagship Pioneering: US-based biotech platform company that creates and grows breakthrough life science companies; directly relevant as Milner's 2025 strategic partner bringing 40+ companies into the Cambridge ecosystem, representing the closest scaled comparison for ecosystem-building activity.
• Curie.Bio: Biotech accelerator and founder support platform that Milner jointly welcomed to Cambridge in 2026 with Cambridge Enterprise; comparable as a therapeutics-focused accelerator providing complementary capital, mentorship, and operational support to early-stage biotech founders.

Broad incumbents

• Scripps Research: Large US-based non-profit biomedical research organization with significant industry partnership activity, technology transfer, and translational research programs; comparable as a broader, more established academic research institute with industry collaboration at scale.
• Cold Spring Harbor Laboratory: Long-established US biomedical research institution with strong industry-academic programs in genetics, genomics, and cancer biology; comparable as an established academic-industry translational research institute with industry collaboration and educational programs in life sciences.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCGdNIMre4xTkKLrcuJgpVGg
• LinkedInlinkedin.com/company/17968809
• Xx.com/TheMilnerInst

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Milner Therapeutics Institute